Moreover, our data revealed a significant association between SPRED3 expression and clinical indicators, including pathologic T stage (P = 0.011), N stage (P < 0.001), and M stage (P = 0.002), and histological type (P < 0.001), residual tumor type (P = 0.021) and extrathyroidal extension (P = 0.019), in thyroid carcinoma patients (Table 3). Here, SPRED3 is linked to neoplasm.